We tested whether panitumumab affected FTD‐induced phosphorylation of ERK1/2 and AKT and observed that cotreatment of panitumumab with FTD for 24 h suppressed FTD‐induced AKT and ERK phosphorylation (Fig. 3). The gene discussed is MAPK1; the disease is frontotemporal dementia.